{"id":"proxalutamide-gt0918","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Muscle spasm"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4594417","moleculeType":"Small molecule","molecularWeight":"517.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of androgens, such as testosterone and dihydrotestosterone, which are involved in the growth and spread of prostate cancer cells. This can help slow or stop the growth of cancer cells.","oneSentence":"Proxalutamide is an androgen receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:36.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer"}]},"trialDetails":[{"nctId":"NCT03899467","phase":"PHASE2","title":"The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC","status":"COMPLETED","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2019-05-30","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":61},{"nctId":"NCT04870606","phase":"PHASE3","title":"Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness","status":"COMPLETED","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2021-03-05","conditions":"Efficacy and Safety","enrollment":733},{"nctId":"NCT05009732","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects","status":"TERMINATED","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2021-09-30","conditions":"Covid19","enrollment":139},{"nctId":"NCT04869228","phase":"PHASE3","title":"A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients","status":"TERMINATED","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2021-08-04","conditions":"COVID-19","enrollment":380},{"nctId":"NCT04103853","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2017-09-06","conditions":"Metastatic Breast Cancer","enrollment":63},{"nctId":"NCT02826772","phase":"PHASE1","title":"Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer","status":"COMPLETED","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2016-02-10","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["standard of care"],"phase":"phase_3","status":"active","brandName":"Proxalutamide (GT0918)","genericName":"Proxalutamide (GT0918)","companyName":"Suzhou Kintor Pharmaceutical Inc,","companyId":"suzhou-kintor-pharmaceutical-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Proxalutamide (GT0918) is a small molecule androgen receptor antagonist used in the treatment of various cancers, including metastatic castrate-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. It is being studied for its efficacy and safety in these conditions, as well as in metastatic breast cancer and COVID-19.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":7,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}